Enamine joins forces with the ICR to expand fragment-based drug discovery with fluorinated compound libraries
KYIV, UKRAINE, September 23, 2025 /EINPresswire.com/ -- Enamine Ltd., a leading global provider of screening compounds, chemical building blocks, and drug discovery services, and The Institute of Cancer Research, London, have announced a new research collaboration aimed at broadening the tools available for Fragment-based Drug Discovery (FBDD).
๐ผ ๐๐ก๐ค๐จ๐๐ง ๐ก๐ค๐ค๐ ๐๐ฉ ๐๐ก๐ช๐ค๐ง๐๐ฃ๐๐ฉ๐๐ ๐๐ง๐๐๐ข๐๐ฃ๐ฉ๐จ
As part of the joint initiative, Enamine will supply a set of fluorinated fragment compounds to The Institute of Cancer Research (ICR), carefully selected from its extensive in-stock collection and Enamine REAL Space. Over the coming months, ICR researchers will profile these compounds using in-house analytical tools, including proton and fluorine NMR spectroscopy, LC-HRMS, and solubility testing.
The annotated compounds will then be screened against the panel of protein targets, helping to assess their potential value in fragment-based screening campaigns. The aim is to produce a well-characterized set of fluorinated fragments that can accelerate early-stage drug discovery for researchers worldwide.
โ๐๐ฉ๐ช๐ด ๐ฆ๐น๐ค๐ช๐ต๐ช๐ฏ๐จ ๐ฏ๐ฆ๐ธ ๐ค๐ฐ๐ญ๐ญ๐ข๐ฃ๐ฐ๐ณ๐ข๐ต๐ช๐ฐ๐ฏ ๐ช๐ด ๐ข ๐จ๐ณ๐ฆ๐ข๐ต ๐ฐ๐ฑ๐ฑ๐ฐ๐ณ๐ต๐ถ๐ฏ๐ช๐ต๐บ ๐ต๐ฐ ๐ค๐ฐ๐ฎ๐ฃ๐ช๐ฏ๐ฆ ๐ต๐ฉ๐ฆ ๐๐๐โ๐ด ๐ณ๐ฆ๐ด๐ฆ๐ข๐ณ๐ค๐ฉ ๐ค๐ข๐ฑ๐ข๐ฃ๐ช๐ญ๐ช๐ต๐ช๐ฆ๐ด ๐ข๐ฏ๐ฅ ๐ฆ๐น๐ฑ๐ฆ๐ณ๐ต๐ช๐ด๐ฆ ๐ช๐ฏ ๐ง๐ณ๐ข๐จ๐ฎ๐ฆ๐ฏ๐ต-๐ฃ๐ข๐ด๐ฆ๐ฅ ๐ฅ๐ณ๐ถ๐จ ๐ฅ๐ช๐ด๐ค๐ฐ๐ท๐ฆ๐ณ๐บ ๐ธ๐ช๐ต๐ฉ ๐๐ฏ๐ข๐ฎ๐ช๐ฏ๐ฆโ๐ด ๐ค๐ฐ๐ฎ๐ฑ๐ฐ๐ถ๐ฏ๐ฅ ๐ฆ๐น๐ฑ๐ฆ๐ณ๐ต๐ช๐ด๐ฆ, ๐ต๐ฐ ๐ค๐ณ๐ฆ๐ข๐ต๐ฆ ๐ด๐ฐ๐ฎ๐ฆ๐ต๐ฉ๐ช๐ฏ๐จ ๐ต๐ณ๐ถ๐ญ๐บ ๐ถ๐ด๐ฆ๐ง๐ถ๐ญ ๐ง๐ฐ๐ณ ๐ต๐ฉ๐ฆ ๐๐๐๐ ๐ค๐ฐ๐ฎ๐ฎ๐ถ๐ฏ๐ช๐ต๐บ. ๐๐ตโ๐ด ๐ข ๐ง๐ฐ๐ค๐ถ๐ด๐ฆ๐ฅ, ๐ฑ๐ณ๐ข๐ค๐ต๐ช๐ค๐ข๐ญ ๐ฑ๐ณ๐ฐ๐ซ๐ฆ๐ค๐ต ๐ธ๐ช๐ต๐ฉ ๐ต๐ฉ๐ฆ ๐ฑ๐ฐ๐ต๐ฆ๐ฏ๐ต๐ช๐ข๐ญ ๐ง๐ฐ๐ณ ๐ธ๐ช๐ฅ๐ฆ ๐ช๐ฎ๐ฑ๐ข๐ค๐ต.โ ๐๐ณ๐ฐ๐ง๐ฆ๐ด๐ด๐ฐ๐ณ ๐๐ธ๐ฆ๐ฏ ๐๐ฐ๐ฆ๐ญ๐ฅ๐ฆ๐ณ, ๐๐ช๐ณ๐ฆ๐ค๐ต๐ฐ๐ณ ๐ฐ๐ง ๐๐ฉ๐ฆ๐ฎ๐ช๐ด๐ต๐ณ๐บ ๐ข๐ต ๐๐ฉ๐ฆ ๐๐ฏ๐ด๐ต๐ช๐ต๐ถ๐ต๐ฆ ๐ฐ๐ง ๐๐ข๐ฏ๐ค๐ฆ๐ณ ๐๐ฆ๐ด๐ฆ๐ข๐ณ๐ค๐ฉ, ๐๐ฐ๐ฏ๐ฅ๐ฐ๐ฏ.
๐๐ง๐ค๐ข ๐๐ค๐๐ฃ๐ฉ ๐ง๐๐จ๐๐๐ง๐๐ ๐ฉ๐ค ๐ง๐๐๐ก-๐ฌ๐ค๐ง๐ก๐ ๐๐ข๐ฅ๐๐๐ฉ
Once testing is complete, Enamine will use the results to refine and commercialize new fragment libraries, making them available through its global distribution network. The ICR will have the priority right to explore the findings and will work with Enamine to publish joint results in peer-reviewed journals.
โ๐๐ฐ๐ญ๐ญ๐ฐ๐ธ๐ช๐ฏ๐จ ๐ฐ๐ถ๐ณ ๐ฑ๐ณ๐ฐ๐ฅ๐ถ๐ค๐ต๐ช๐ท๐ฆ ๐ค๐ฐ๐ญ๐ญ๐ข๐ฃ๐ฐ๐ณ๐ข๐ต๐ช๐ฐ๐ฏ ๐ธ๐ช๐ต๐ฉ ๐๐๐ ๐ฐ๐ฏ ๐ต๐ฉ๐ฆ ๐ฅ๐ฆ๐ด๐ช๐จ๐ฏ ๐ฐ๐ง ๐๐ข๐ณ๐ฃ๐ฐ๐น๐บ๐ญ๐ช๐ค ๐๐ค๐ช๐ฅ ๐๐ช๐ฐ๐ช๐ด๐ฐ๐ด๐ต๐ฆ๐ณ๐ฆ ๐๐ณ๐ข๐จ๐ฎ๐ฆ๐ฏ๐ต ๐๐ช๐ฃ๐ณ๐ข๐ณ๐บ, ๐ธ๐ฆโ๐ณ๐ฆ ๐ฆ๐น๐ค๐ช๐ต๐ฆ๐ฅ ๐ต๐ฐ ๐ซ๐ฐ๐ช๐ฏ ๐ฆ๐ง๐ง๐ฐ๐ณ๐ต๐ด ๐ฐ๐ฏ๐ค๐ฆ ๐ข๐จ๐ข๐ช๐ฏ ๐ต๐ฐ ๐ฅ๐ฆ๐ท๐ฆ๐ญ๐ฐ๐ฑ ๐ข ๐ฏ๐ฐ๐ท๐ฆ๐ญ ๐ง๐ณ๐ข๐จ๐ฎ๐ฆ๐ฏ๐ต ๐ญ๐ช๐ฃ๐ณ๐ข๐ณ๐บ ๐ต๐ข๐ช๐ญ๐ฐ๐ณ๐ฆ๐ฅ ๐ง๐ฐ๐ณ ๐ง๐ญ๐ถ๐ฐ๐ณ๐ช๐ฏ๐ฆ-๐ฃ๐ข๐ด๐ฆ๐ฅ ๐๐๐ ๐ด๐ค๐ณ๐ฆ๐ฆ๐ฏ๐ช๐ฏ๐จ. ๐๐ฉ๐ช๐ด ๐ฑ๐ณ๐ฐ๐ซ๐ฆ๐ค๐ต ๐ณ๐ฆ๐ง๐ญ๐ฆ๐ค๐ต๐ด ๐ฐ๐ถ๐ณ ๐ด๐ฉ๐ข๐ณ๐ฆ๐ฅ ๐ค๐ฐ๐ฎ๐ฎ๐ช๐ต๐ฎ๐ฆ๐ฏ๐ต ๐ต๐ฐ ๐ฆ๐น๐ฑ๐ข๐ฏ๐ฅ๐ช๐ฏ๐จ ๐ต๐ฉ๐ฆ ๐๐๐๐ ๐ต๐ฐ๐ฐ๐ญ๐ฃ๐ฐ๐น ๐ธ๐ช๐ต๐ฉ ๐ช๐ฏ๐ฏ๐ฐ๐ท๐ข๐ต๐ช๐ท๐ฆ ๐ข๐ฏ๐ฅ ๐ค๐ฉ๐ฆ๐ฎ๐ช๐ค๐ข๐ญ๐ญ๐บ ๐ฅ๐ช๐ท๐ฆ๐ณ๐ด๐ฆ ๐ด๐ต๐ข๐ณ๐ต๐ช๐ฏ๐จ ๐ฑ๐ฐ๐ช๐ฏ๐ต๐ด,โ ๐ด๐ข๐ช๐ฅ ๐๐ฏ๐ฅ๐ณ๐ฆ๐บ ๐๐ข๐ณ๐ฏ๐ฐ๐ท๐ด๐ฌ๐ช๐บ, ๐๐ข๐ญ๐ฆ๐ด ๐๐ช๐ณ๐ฆ๐ค๐ต๐ฐ๐ณ, ๐๐ถ๐ณ๐ฐ๐ฑ๐ฆ, ๐๐ฏ๐ข๐ฎ๐ช๐ฏ๐ฆ.
๐๐๐๐ฉโ๐จ ๐ฃ๐๐ญ๐ฉ
The project is expected to run for 12 months, with the option to extend. Both teams will contribute to a final research report, and future communications will highlight key takeaways for the scientific and drug discovery communities.
About Enamine Ltd.
Enamine Ltd., headquartered in Kyiv, Ukraine, is a scientifically driven contract research organization renowned for maintaining the worldโs largest and most reputable collections of Building Blocks (over 300,000), Screening Compounds (4.6 million), and vast chemical database of synthetically feasible structures โ REAL Space, comprising trillions of molecules. The company offers an extensive portfolio of expertly designed libraries for hit discovery, including Diversity, Fragment, Covalent, Bioactive, and Targeted Libraries. Enamine delivers fully integrated discovery services, encompassing advanced organic synthesis, library synthesis, medicinal chemistry support, high-throughput screening (HTS), and preclinical biology, advancing life science and pharmaceutical research efforts globally.
About The Institute of Cancer Research
The Institute of Cancer Research, London, is an independent research institute based across two London sites: one in Chelsea in the centre and one in Sutton in the south. We are a member of the University of London and have an outstanding record of achievement dating back more than 100 years.
Around 800 scientists work at The Institute of Cancer Research (ICR) across the full spectrum of cancer research, from basic cancer biology to clinical trials. We are also one of the worldโs most successful academic institutions in industry collaboration.
Media Contacts
Andrey Tarnovskiy
Enamine Ltd.
email us here
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
